In an interview with ACT senior editor Andy Studna at SCOPE Summit, Davidson, vice president, product lead - sponsor tech strategy, Advarra, discussed ongoing challenges in study startup processes, ...
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...